01Core principlesThe concepts and mechanisms needed to understand the subject.
Benign histology ranges from changes that do not materially alter future breast-cancer risk to epithelial proliferations that mark a sustained increase. Usual ductal hyperplasia and some sclerosing lesions differ biologically from atypical ductal hyperplasia, atypical lobular hyperplasia and lobular carcinoma in situ. The latter diagnoses may be found around another imaging target and can be distributed beyond the sampled focus, so a small core cannot always define their full extent.
Two decisions must not be conflated. First, does the pathology adequately explain the current mammographic or ultrasound lesion, or could adjacent ductal carcinoma in situ or invasive disease remain? Second, after the present target is resolved, what is the patient’s longer-term absolute risk and which preventive options fit their values and contraindications? The 2024 European B3 guidance supports lesion-specific multidisciplinary assessment, while NICE CG164 supplies a UK framework for surveillance, genetics referral and risk-reducing choices in people with familial risk.
Key points
- Benign breast disease is not one risk category: non-proliferative change, proliferative disease without atypia, atypical ductal or lobular hyperplasia and lobular carcinoma in situ carry different implications.
- Atypical hyperplasia is both a marker of elevated future bilateral risk and a possible incompletely sampled neighbour of carcinoma, so immediate lesion concordance and long-term risk assessment are separate questions.
- Lobular neoplasia may be incidental and multifocal; classical and pleomorphic forms do not share identical management, and the imaging target must be explained.
- A core result labelled B3 or uncertain malignant potential triggers multidisciplinary review of lesion type, sampling volume, atypia and residual imaging abnormality before surveillance or excision is chosen.
- Future-risk estimates combine pathology with age, family pedigree, reproductive factors, breast density, previous cancer and pathogenic variants rather than multiplying one headline relative risk.
- Risk-reducing medication, enhanced imaging or surgery requires specialist calculation and shared decision making about absolute benefit, adverse effects and alternatives.
02Mechanisms and patternsImportant relationships and how to distinguish them.
ADH resembles low-grade ductal carcinoma in situ but is limited in extent; a core cannot reliably establish the full extent, so residual calcification, sample volume and radiology-pathology concordance determine how the current target is completed.
Atypical lobular hyperplasia and classical LCIS can be incidental bilateral risk markers. If classical morphology is concordant and the imaging target is otherwise explained, management differs from a lesion that remains radiologically unexplained.
Pleomorphic or florid LCIS has more concerning cytology or extent and is not managed as interchangeable with incidental classical LCIS; specialist excision and concordance decisions address the immediate lesion before future-risk counselling.
NICE defines moderate familial risk as lifetime risk at least 17% but below 30%, and high risk as 30% or greater. These categories require a relevant familial assessment and are not assigned automatically by atypia alone.
03Interpreting evidenceInformation, measurements and their limitations.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Pathology report review - Why
- Identify the exact proliferative diagnosis, atypia, extent in cores and any features requiring complete excision.
- Interpretation and limitations
- Benign is insufficient shorthand. Confirm whether the report describes usual hyperplasia, atypical ductal hyperplasia, lobular neoplasia, radial scar, papilloma or another B3 entity.
- 02
Radiology-pathology concordance - Why
- Determine whether the sampled lesion explains the original mass, calcification or distortion.
- Interpretation and limitations
- Incidental atypia in tissue that does not explain suspicious imaging leaves the target unresolved. Calcification retrieval and residual lesion are reviewed explicitly.
- 03
Individual risk calculation - Why
- Translate pathology, pedigree and personal factors into absolute risk over a stated period.
- Interpretation and limitations
- Use a validated tool appropriate to the population and enter verified family ages and diagnoses. Model output is an estimate, not a genetic test or certainty.
- 04
Genetics and surveillance assessment - Why
- Identify people whose family or tumour history meets specialist criteria for counselling, testing or enhanced imaging.
- Interpretation and limitations
- Pathology alone may not determine eligibility. Combine related breast, ovarian, pancreatic and prostate cancers, age at diagnosis and any known familial variant.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked case: target closure, moderate familial risk and preventionSeparate a resolved B3 lesion from an independent risk planA fictional teaching case describes a 52-year-old postmenopausal woman whose 14 mm calcification cluster is completely removed by vacuum-assisted excision; final histology shows ADH only, with no DCIS or invasive carcinoma.+
- 1At multidisciplinary review, confirm specimen radiography retrieved the calcification, post-procedure imaging shows no residual target, and pathology is concordant ADH without carcinoma. The current B3 lesion is therefore closed rather than treated as cancer.
- 2The risk clinic verifies a pedigree containing one mother diagnosed at 48 and a maternal aunt at 57, confirms no known pathogenic variant or prior breast cancer, and documents a 19% lifetime estimate using its stated validated method. This supplied fictional result falls in NICE's moderate 17% to under 30% category; it is not an author-performed model calculation.
- 3After discussing that current NHSBSP guidance permits routine screening following a non-upgraded, completely removed B3 target, she chooses the separate NICE moderate familial-risk option of annual mammography for the rest of ages 50 to 59. The regional familial-risk service accepts responsibility and books her next mammogram for 12 months after the completing VAE.
- 4After confirming postmenopausal status, no severe osteoporosis, baseline bone assessment and no conflicting oestrogen therapy, the patient chooses anastrozole 1 mg by mouth once daily for 5 years through an experienced prescriber and shared-care plan.
- 5The record now contains the no-residual-target MDT outcome, the supplied 19% estimate and assumptions, and the familial-risk service's annual-mammography booking. Baseline DXA shows a T-score of -1.1, so the shared-care prescriber dispenses anastrozole with a 5-year stop date; at the planned 8-week review she reports daily adherence and no new limiting adverse effect, and continuation with the documented bone-health plan is confirmed.
02Risk-consultation pathwayMatch prevention to risk and menopausal statusA resolved atypical lesion prompts a separate familial-risk assessment and the patient wants absolute choices rather than a relative-risk headline.+
- 1First confirm that the current lesion is resolved. If ADH was diagnosed on limited core and substantial target calcification remains, complete diagnostic assessment or removal through the B3 multidisciplinary team using the appropriate vacuum-assisted or surgical route before future-risk care; once closed, verify family diagnoses and ages, pathology and other model inputs and record the absolute-risk method, time horizon and assumptions.
- 2Keep lesion follow-up separate: B3 with no upgrade may return to routine NHSBSP screening, while an independently established NICE moderate or high familial-risk category can change age-specific mammographic surveillance.
- 3For premenopausal high risk, NICE offers tamoxifen for 5 years and considers it at moderate risk, avoiding it with past or increased thromboembolic or endometrial-cancer risk. For postmenopausal high risk, NICE offers anastrozole for 5 years and considers it at moderate risk, avoiding it with severe osteoporosis.
- 4Use a specialist shared decision about expected absolute benefit, menopausal status, uterus, VTE and bone health, interactions and adverse effects; record the chosen option, prescriber, monitoring and 5-year stop date.
03Lobular-neoplasia pathwayResolve morphology and target before future-risk counsellingCore from an imaging abnormality reports lobular neoplasia, and the team must decide whether the finding explains the target.+
- 1Ask pathology to distinguish atypical lobular hyperplasia, classical LCIS and nonclassical pleomorphic or florid LCIS rather than using lobular neoplasia as the only management label.
- 2Check whether the lobular finding is incidental or accounts for the mass, calcification or distortion, and document residual abnormality and sample adequacy.
- 3Obtain further representative tissue or excision for discordance or nonclassical morphology according to the specialist B3 pathway; do not let future bilateral risk counselling substitute for current-target diagnosis.
- 4After lesion closure, perform the separate absolute-risk, genetics, surveillance and prevention assessment using the complete pathology and verified personal context.
05Relevant medicines and safetySpecific regimens and precautions where medicines are relevant.
Anastrozole
For primary prevention in an appropriately selected postmenopausal woman at moderate or high breast-cancer risk: 1 mg by mouth once daily for 5 years under an experienced prescriber and shared-care arrangement.Do not use in pregnancy, breastfeeding or premenopausal women, and do not combine with tamoxifen or oestrogen-containing therapy. Assess fracture and bone-mineral-density risk before and during treatment; severe osteoporosis makes it unsuitable in the NICE prevention pathway, and cardiovascular, joint and menopausal adverse effects require review.
Tamoxifen
For primary prevention in an appropriately selected woman at moderate or high breast-cancer risk: 20 mg by mouth once daily for 5 years under an experienced prescriber and shared-care arrangement.For prevention, avoid with a history of deep-vein thrombosis or pulmonary embolism, increased thromboembolic or endometrial-cancer risk, pregnancy, or concurrent coumarin anticoagulants; do not combine with anastrozole. Exclude pregnancy before treatment and use barrier or other adequate non-hormonal contraception while sexually active; do not attempt conception during treatment or for 2 months after stopping. Tamoxifen is not recommended during breastfeeding. Avoid potent CYP2D6 inhibitors such as paroxetine, fluoxetine or bupropion where possible through prescriber-led medication review. Check QT-prolonging combinations and use electrolyte and ECG assessment for patients with QT risk factors rather than testing everyone. Discuss uterine bleeding and VTE symptoms and stop at least 6 weeks before elective surgery.
06Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
- Track every B3 diagnosis to a documented multidisciplinary endpoint: target completely removed or otherwise explained, final pathology, upgrade status and the screening route that follows.
- Record the source, model or formal method, time horizon and verified assumptions for any numerical risk result; update the pedigree when relatives receive relevant cancer or genetic diagnoses.
- Do not schedule universal annual imaging for atypia alone. Record whether surveillance is routine NHSBSP after no upgrade or enhanced because a separate familial or genetic criterion is met, with modality, interval, age range and responsible service.
- For anastrozole prevention, document baseline and interval bone-density assessment, musculoskeletal or menopausal adverse effects, adherence, interacting oestrogen therapy and the 5-year stop date. For tamoxifen, exclude pregnancy, document adequate non-hormonal contraception and the 2-month post-treatment conception interval, avoid breastfeeding, review strong CYP2D6 and QT-prolonging medicines, monitor VTE and uterine warning symptoms, and record the 6-week preoperative interruption plan; ECG and electrolytes are targeted to QT risk factors.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Benign and low risk differ
A lesion can be non-malignant today yet signal increased future risk. Communicate both truths without describing atypia as cancer or as irrelevant.
Upgrade is about sampling
Finding carcinoma on excision after atypical hyperplasia does not mean atypia transformed during the interval; it usually reflects adjacent disease not represented by the original cores.
Risk is usually bilateral
Atypical hyperplasia and lobular neoplasia mark susceptibility beyond the sampled site, so future counselling considers both breasts rather than only excision margins.
Models need verified inputs
A risk calculator can look precise while using inaccurate family ages or diagnoses. Record the model, time horizon and assumptions so estimates can be revisited.
08Common pitfallsFrequent interpretation and management errors.
- 01
Telling a patient every benign biopsy returns them to population risk erases the significance of epithelial atypia and lobular neoplasia.
- 02
Treating atypical hyperplasia on limited core as a completed diagnosis can miss adjacent ductal carcinoma in situ in residual calcification.
- 03
Quoting only a relative-risk multiplier prevents informed comparison of surveillance, medication harms and absolute benefit.
- 04
Calling classical and pleomorphic lobular neoplasia interchangeable ignores differences in morphology, concordance and immediate management.